COMPANY:

HTG Molecular Diagnostics

"HTG Molecular Diagnostics, Inc...today announced there will be at least four scientific posters featuring its proprietary HTG EdgeSeq™ technology presented at the American Association for Cancer Research Annual Meeting (AACR) April 16-19 in Orlando, Florida."

"HTG Molecular Diagnostics, Inc...today announced there will be at least eight scientific abstracts featuring HTG’s proprietary HTG EdgeSeq™ technology presented at the 45th Annual San Antonio Breast Cancer Symposium (SABCS 2022) and at the 64th Annual American Society of Hematology (ASH) Annual Meeting."

"HTG Molecular Diagnostics, Inc...and OmiCure®, a leading European digital health company that develops and markets explainable AI-based therapeutic decision support software, announced a collaboration with OmiCure to implement the HTG Transcriptome Panel (HTP) as an alternative to RNA-Seq to inform the OmiCure test and help guide therapeutic decision-making across several cancer types."

"HTG Molecular Diagnostics, Inc...announced that the Fundación Instituto Valenciano de Oncología, located in Valencia, Spain (IVO), with its partners, the Fundación Pública Andaluza Progreso y Salud (FPS) and the Centro de Investigación Biomédica en Red (CIBER), have developed a laboratory-developed test (LDT) (the MPD Test) for the assessment of breast cancer recurrence based on their use of the HTG EdgeSeq™ technology."

"HTG Molecular Diagnostics...announced the customer publication of a peer reviewed journal article featuring the HTG Transcriptome Panel (HTP) less than one year after the breakthrough product’s commercial release...The article, published in Frontiers in Medicine by one of several participants in the Company’s HTP Early Adopter Program, applied the comprehensive HTP to query 19,398 mRNA targets in an effort to advance the understanding of how best to treat bladder cancer patients who do not fall into categories identified by routine tissue staining."

"HTG Molecular Diagnostics, Inc...announced its HTG EdgeSeq technology was highlighted in multiple scientific abstracts at the 2022 American Society of Clinical Oncology (ASCO) conference held in Chicago, Illinois...Abstracts were presented by HTG’s key biopharma customers and scientific collaborators from both the United States and Europe highlighting the unique features, benefits and results utilizing HTG’s proprietary HTG EdgeSeq gene expression profiling (GEP) technology. Prominent among the research presented was the HTG Transcriptome Panel (HTP). The HTP, released for commercial use in August 2021, enables the capture of comprehensive and reliable human transcriptome data using a fraction of the sample typically required by other GEP methods." "

"HTG Molecular Diagnostics, Inc...announced that it has improved the sample preparation protocol for its miRNA Whole Transcriptome Assay (miRNA WTA) so that it is now harmonized with the HTG Transcriptome Panel (HTP)...The harmonized protocol is designed to enable customers to process a single sample with HTG’s nearly 20,000 gene mRNA and 2,000+ miRNA transcriptome panels using a single sample lysate."

"HTG Molecular Diagnostics, Inc...expanded the potential markets and applications for its pioneering HTG Transcriptome Panel (HTP). Since launching HTP with commercial availability in the US and Europe in August 2021, HTG has completed validation of additional sample types that are more commonly used outside of oncology, and also expanded sequencing capabilities to facilitate easier testing of larger sample cohorts...Initially validated for neoplastic tissue, HTG has now validated HTP for use with normal FFPE tissue and other non-neoplastic tissues. In addition, the panel has been validated with PAXgene, a popular liquid blood-based sample type, and with extracted RNA from both fresh frozen and FFPE tissue samples."

"HTG Molecular Diagnostics, Inc...announced that it has exceeded $1 million of revenue recognized from sales of its HTG Transcriptome Panel (HTP) as of November 30, 2021. HTP was launched with commercial availability in the United States and Europe in early August 2021."

"HTG Molecular Diagnostics...and the Icahn School of Medicine at Mount Sinai (Icahn Mount Sinai)...announced they have entered into a new research collaboration as part of HTG’s Transcriptome Panel Early Adopter Program. HTG will provide in-kind laboratory services utilizing its proprietary HTG EdgeSeq technology in connection with multiple Icahn Mount Sinai bladder cancer studies."